Sieben Schlüsselstrategien für Europa zur Vorbereitung auf eine Opioidkrise

Zusammenfassung

Ziel In den vergangenen zwei Jahrzehnten haben der Konsum synthetischer Opioide (SO) und die damit verbundenen negativen Folgen weltweit drastisch zugenommen. Die hochpotenten SO schaffen einen komplexen und unberechenbaren Markt, der neue Herausforderungen mit sich bringt.

Methodik Das europäische Forschungsprojekt „Stärkung der Reaktionsbereitschaft von Gesundheitssystemen auf den potenziellen Anstieg der Prävalenz und des Konsums von synthetischen Opioiden“ hat Leitlinien entwickelt, mit denen das Gesundheitssystem auf die Herausforderungen durch SO reagieren kann.

Ergebnisse Diese Leitlinien konzentrieren sich auf Interventionen für Menschen, die SO konsumieren. Sie beinhalten sieben Schlüsselstrategien: Frühwarnsysteme, Internet-Monitoring, E-Health, Drug-Checking, Drogenkonsumräume, Naloxon sowie Opioid-Agonisten-Therapie (OAT). Während einige Strategien längst etabliert sind (z. B. Drogenkonsumräume), herrscht in anderen Bereichen (z. B. Drug-Checking) noch deutlicher Nachholbedarf.

Schlussfolgerung Herkömmliche Maßnahmen sowie einzelne Ansätze reichen nicht aus, um einer möglichen Opioidkrise in Europa adäquat zu begegnen. Es ist im Interesse der SO-Konsumierenden und des Gesundheitssystems, innovative Maßnahmen mit etablierten Mitteln zu kombinieren. Der Schlüssel zum Erfolg liegt in der Integration verschiedener Ansätze.

Abstract

Purpose Over the past two decades, the use of synthetic opioids (SO) and the associated negative consequences have increased dramatically worldwide. The highly potent SO create a complex and unpredictable market that brings new challenges.

Methods The European research project "Strengthening Synthetic Opioids Health Systems´ Preparedness to respond to the Potential Increases in Prevalence and Use of Synthetic Opioids“ developed guidelines to help health systems respond to the challenges posed by SO.

Results These guidelines focus on interventions for people who use SO. They include seven key strategies: Early Warning Systems, Internet Monitoring, E-Health, Drug Checking, Drug Consumption Rooms, Naloxone, and Opioid Agonist Therapy (OAT). While some strategies have long been established (e. g. drug consumption rooms), there is still a lot of catching up to do in other areas (e. g. drug checking).

Conclusion Conventional measures as well as individual approaches are not sufficient to adequately address a possible opioid crisis in Europe. It is in the interest of SO users and the health system to combine innovative measures with established means. The key to success lies in the integration of different approaches.

Schlüsselwörter

synthetische Opioide - Fentanyl - Opioidkonsum - Opioid-Agonisten-Therapie

Keywords

synthetic opioids - fentanyl - opioid use - Opioid Agonist Treatment (OAT)

Publikationsverlauf

Artikel online veröffentlicht:
22. Mai 2024

• Literatur

• 1 Europäische Beobachtungsstelle für Drogen und Drogensucht. Europäischer Drogenbericht 2022: Trends und Entwicklungen. Luxemburg. 2022
• 2 Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Current Opinion in Psychiatry 2021; 34: 344-350
• 3 Glaeske G, Ernst A, Höfel F. et al. Opioidreport 2022. Bremen. 2022
• 4 Seyler T, Giraudon I, Noor A. et al. Is Europe facing an opioid epidemic: What does European monitoring data tell us. European Journal of Pain 2021; 25: 1072-1080
• 5 Uusküla A, Talu A, Vorobjov S. et al. The fentanyl epidemic in Estonia: factors in its evolution and opportunities for a comprehensive public health response, a scoping review. International Journal of Drug Policy 2020; 81: 102757
• 6 SO-PREP. 2023; Im Internet: https://so-prep-project.eu/ Stand: 24.11.2023
• 7 Abel-Ollo K, Andree R, Colman C. et al. Toolkit on key responses to synthetic opioids. 2022
• 8 Official Journal of the European Communities. Joint action of 16 June 1997 adopted by the Council on the basis of Article K.3 of the Treaty on European Union, concerning the information exchange, risk assessment and the control of new synthetic drugs. 1997
• 9 European Monitoring Centre for Drugs and Drug Addiction. EMCDDA operating guidelines for the European Union Early Warning System on new psychoactive substances. 2021
• 10 United Nations. National Early Warning Systems. Considerations, stakeholders and communication. Im Internet https://syntheticdrugs.unodc.org/syntheticdrugs/en/earlywarning/national-early-warning-systems.html Stand: 24.11.2023
• 11 Barratt MJ, Aldridge J. Everything you always wanted to know about drug cryptomarkets* (*but were afraid to ask). International Journal of Drug Policy 2016; 35: 1-6
• 12 Décary-Hétu D. Online crime monitoring. In: Rossy Q, Décary-Hétu D, Delémont O, et al., Hrsg. The Routledge international handbook of forensic intelligence and criminology. 2017
• 13 Zhang MWB, Ho RCM. Tapping onto the Potential of Smartphone Applications for Psycho-Education and Early Intervention in Addictions. Front Psychiatry 2016; 7
• 14 Päihdelinkki. Im Internet: https://paihdelinkki.fi/ Stand: 24.11.2023
• 15 MySafeRx. Im Internet: http://mysaferx.org/ Stand: 24.11.2023
• 16 Kanter K, Gallagher R, Eweje F. et al. Willingness to use a wearable device capable of detecting and reversing overdose among people who use opioids in Philadelphia. Harm Reduct J 2021; 18: 75
• 17 Deutscher Bundestag. Drucksache 20/7397
• 18 Deutsche Aidshilfe. RaFT. 2023; Im Interne:t https://www.drogenkonsumraum.de/de/raft; Stand: 24.11.2023
• 19 Karamouzian M, Dohoo C, Forsting S. et al. Evaluation of a fentanyl drug checking service for clients of a supervised injection facility, Vancouver, Canada. Harm Reduct J 2018; 15: 46
• 20 Wallace B, Van Roode T, Pagan F. et al. The potential impacts of community drug checking within the overdose crisis: qualitative study exploring the perspective of prospective service users. BMC Public Health 2021; 21: 1156
• 21 European Monitoring Centre for Drugs and Drug Addiction. Harm reduction :evidence, impacts and challenges: EMCDDA monographs. LU: Publications Office; 2010
• 22 Stöver DH, Förster S. Auswertung der Daten der vier Frankfurter Drogenkonsumräume. 2021
• 23 Notta D, Black B, Chu T. et al. Changing risk and presentation of overdose associated with consumption of street drugs at a supervised injection site in Vancouver, Canada. Drug and Alcohol Dependence 2019; 196: 46-50
• 24 Olsen A, McDonald D, Lenton S. et al. Assessing causality in drug policy analyses: How useful are the Bradford Hill criteria in analysing take-home naloxone programs?. Drug Alcohol Rev 2018; 37: 499-501
• 25 Strang J. Take-Home Naloxone and the Prevention of Deaths from Heroin Overdose: Pursuing Strong Science, Fuller Understanding, Greater Impact. European Addiction Research 2022; 28: 161-175
• 26 Deutsche Aidshilfe, Hrsg. Naloxon rettet Leben! 2024
• 27 Carpenter J, Murray BP, Atti S. et al. Naloxone Dosing After Opioid Overdose in the Era of Illicitly Manufactured Fentanyl. J Med Toxicol 2020; 16: 41-48
• 28 Sordo L, Barrio G, Bravo MJ. et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017; j1550
• 29 Sundararajan K, Ajrawat P, Canizares M. et al. The potential for diversion of prescribed opioids among orthopaedic patients: Results of an anonymous patient survey. PLoS ONE 2021; 16: e0256741
• 30 Pearce LA, Min JE, Piske M. et al. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. BMJ 2020; m772